Abstract: A system and method are provided for determining an expected life of an electric surge protection component. The system and method monitors preferably each surge that an electric surge protection component experiences. Each surge is measured to determine magnitude and duration, and a cumulative surge measurement history is maintained for each component. Based upon an analysis of the cumulative surge measurement history, an expected life of the component is determined, and an end user is alerted at or preferably near an end of the expected life of the device.

Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.

Abstract: Compounds that selectively inhibit the binding of ligands to ?4?1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion.

Abstract: A self test (ST) ground fault circuit interrupter (GFCI) provides improved end of life (EOL) detection by rejecting false EOL information. A processing device receives fault detection signals indicating when faults are detected, and input signals indicating when contacts used to interrupt power to a load are closed. The processing device rejects the fault detection signals when they fail to meet a selected condition and the contacts are closed, and declares end of life (EOL) when the selected condition is met. The fault detection signals can correspond to pulses at an output of a gated device between the processing device and a GFCI chip, and the selected condition can be a selected integer number of pulses.

Abstract: A self testing fault detector having a line side and a load side and a conductive path there between. The apparatus includes a solenoid, which is adapted to move a plurality of contacts disposed in the conductive path from a first position to a second position when the self testing device is powered from the line side; and a processor, which is adapted to energize the solenoid using a first switch and maintain said solenoid in the energized state using a second switch.

Abstract: There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

Abstract: A bias device that modifies the bias of a device based on an input signal to the device. The device may have a fixed bias, and the bias device can be connected in parallel with the fixed bias. The device can be an amplifier, such as a linear amplifier or a class AB amplifier. The bias device can be configured to provide maximum bias during the device's crossover time period.

Abstract: A self testing fault detector having a line side and a load side and a conductive path there between, said apparatus is provided. The self testing fault detector includes a controller, adapted to perform periodic status tests on a protection circuit of the self testing fault detector without interrupting power to the load.

Abstract: A method for calling a software method in a called CORBA application by a caller software method in a caller CORBA application in a process of a computer system is disclosed. The caller software method calls a software method in a CORBA stub sending a parameter which is created using a classloader of the caller application. The CORBA stub software method calls a software method in a dynamic proxy sending the parameter. The dynamic proxy software method calls an ORB sending the parameter. The ORB serializes the parameter and returns it to the dynamic proxy software method. The dynamic proxy software method calls the ORB sending the serialized parameter. The ORB deserializes the serialized parameter using a classloader of the called application and returns it to the dynamic proxy software method. The dynamic proxy software method calls the called software method sending the deserialized parameter.

Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

Abstract: An apparatus (22,44) is described for use in generating configuration information for a computer system (12) employing hierarchical entities. A policy template (24) is employed which contains a definition of an abstract high-level policy, for the configuration of the system, and permitted refinements to that policy, the definition referring to a plurality of the entities. An information and system model (16) contains information about the computer system and its environment including the entities referred to in the high-level policy definition, the hierarchy thereof and non-hierarchical relations between the entities. A policy authoring engine (26) refines the high-level policy definition with reference to the permitted refinements thereto and the stored information about the entities to which the high-level policy definition relates in order to produce a refined policy definition.

Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-? expression utilizing compounds of the present invention are also disclosed.

Abstract: Nitrogen heterocycle biaryls having a carboxylate terminus are useful for treating endometriosis, osteoporosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity. Compounds of formula: are disclosed.

Abstract: The present invention includes a MOS device (100) that has a P-type substrate (102) and an N-type drain region (104) formed within the substrate (102). An annular N-type source region (106) generally surrounds the drain region (104). The source region (106) serves as both the source for the MOS device (100) and a sacrificial collector guard ring for an electrostatic discharge protection circuit. An annular gate region (110) generally surrounds the drain region (104) and is electrically insulated from the drain region (104) and electrically connected to the source region (106). An annular P-type bulk region (108) generally surrounds the source region (106) and is electrically connected to the source region (106).

Abstract: An orally deliverable pharmaceutical composition comprises a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, said composition exhibiting at least one of (a) an in vitro release profile wherein on average no more than about 20% of the pramipexole is dissolved within 2 hours after placement of the composition in a standard dissolution test; and (b) an in vivo pramipexole absorption profile following single dose administration to healthy adult humans wherein the time to reach a mean of 20% absorption is greater than about 2 hours and/or the time to reach a mean of 40% absorption is greater than about 4 hours. The composition is useful for oral administration, not more than once daily, to a subject having a condition or disorder for which a dopamine receptor agonist is indicated.

Abstract: Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.

Abstract: A ground fault interrupter apparatus is provided that employs a switching device that is operated in two stages. The first stage operates a solenoid in order to close the contacts and preferably provides coupling between the load and the power source. The second stage maintains the coupling, however, drawing less current and power from the internal devices of the apparatus. Accordingly, the fault interrupter meets various standards for the time required to open and close the contacts as well as keeping the dissipated heat from the device within the required range.

Abstract: A method for calling a software method in a called CORBA application by a caller software method in a caller CORBA application in a process of a computer system is disclosed. The caller software method calls a software method in a CORBA stub sending a parameter which is created using a classloader of the caller application. The CORBA stub software method calls a software method in a dynamic proxy sending the parameter. The dynamic proxy software method calls an ORB sending the parameter. The ORB serializes the parameter and returns it to the dynamic proxy software method. The dynamic proxy software method calls the ORB sending the serialized parameter. The ORB deserializes the serialized parameter using a classloader of the called application and returns it to the dynamic proxy software method. The dynamic proxy software method calls the called software method sending the deserialized parameter.

Abstract: The present invention relates to a reverse bias protection structure which comprises a PMOS transistor structure having a drain portion, a gate portion, a source portion and a backgate portion, wherein the gate portion is coupled to a first voltage potential, the source portion is selectively coupleable to a power supply, and the drain portion is selectively coupleable to a circuit needing power to be supplied thereto from the power supply. The reverse bias protection structure further comprises a Schottky diode structure having an anode coupled to the source portion of the PMOS transistor structure, and a cathode coupled to the backgate portion of the PMOS structure. Under forward bias conditions, the PMOS transistor conducts and exhibits a small voltage drop thereacross. Under reverse bias conditions, the PMOS transistor is off and the Schottky structure is reverse biased, thus preventing current through the protection structure.